By Mill Chart
Last update: Jun 4, 2025
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) was identified by our stock screener as a potential value opportunity. The company, which focuses on rare disease therapies, shows strong profitability and financial health while trading at a reasonable valuation. Let’s examine why BMRN stands out.
BMRN’s valuation metrics suggest it may be undervalued compared to industry peers:
The stock’s PEG ratio, which accounts for growth, further supports its appeal as reasonably priced.
BMRN’s profitability metrics are impressive:
Recent earnings growth (136.8% YoY EPS increase) adds to the bullish case.
The company maintains a solid balance sheet:
While share dilution has occurred, strong free cash flow coverage of debt mitigates concerns.
BMRN’s growth outlook remains positive:
Though revenue growth may slow slightly, earnings momentum remains intact.
Our Decent Value Stocks screener lists more stocks with similar characteristics. For a deeper look, review the full fundamental report on BMRN.
This is not investing advice! The article highlights observations at the time of writing, but you should conduct your own analysis before making investment decisions.
56.11
-0.68 (-1.2%)
Find more stocks in the Stock Screener
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) appears undervalued with strong profitability, financial health, and growth potential, making it a candidate for value investors.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.